Peripheral Subcutaneous Field Stimulation (PSFS) Coverage Policy
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Iowa policy alerts
Know when Blue Cross Blue Shield - Iowa releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Wellmark/BCBS Iowa's coverage stance for peripheral subcutaneous field stimulation to treat chronic neuropathic pain and related indications; applies to providers requesting coverage determinations for members under Wellmark plans.
No material clinical or coverage changes in this revision.
Coverage Determination and Evidence Summary
inv-01: Not covered — investigational
Coverage determination
Based on randomized trials, nonrandomized comparative studies, and case series with methodological limitations, short follow-up, and device-related adverse events; larger controlled trials comparing PFS/PNFS with placebo or alternative treatments are needed.
inv-02: Evidence summary / contexts with observed benefit
Evidence summary and situations where benefit was observed
Both trials had important limitations including lack of blinding (crossover RCT lacked sham/comparator), high loss to follow-up, and early termination for recruitment difficulties; device-related adverse events were reported.
Adverse events reported across series include lead dislocation/fracture, infection, lead/battery migration, and unpleasant sensations.
ASPN/other society guidance may discuss implantable peripheral nerve stimulation broadly, but some guidelines do not specifically endorse routine use of subcutaneous field stimulation given evidence limitations.
Peripheral subcutaneous field stimulation (PSFS) is described in regulatory context as an off-label use of FDA‑approved peripheral nerve stimulation systems that are indicated for chronic pain by targeting peripheral nerves. The policy notes this regulatory status when considering coverage and exclusions.
The National Institute for Health and Care Excellence (NICE) concluded that the available evidence for peripheral nerve‑field stimulation is limited in both quantity and quality, with a limited duration of follow‑up, and that safety data are also limited; NICE did not recommend routine use given these evidence limitations.
Within the cited document excerpts there are no explicit clinical exclusions listed for peripheral subcutaneous field stimulation; coding guidance and general reporting instructions are provided, but specific patient exclusion criteria are not specified in these chunks.
This policy states that peripheral subcutaneous field stimulation is considered investigational for all indications and, as such, is regarded as not medically necessary under the terms of this policy.
NICE’s assessment emphasizes that when high‑quality evidence is lacking or long‑term benefit has not been demonstrated, the therapy may be considered investigational; this conclusion supports treating peripheral subcutaneous field stimulation as investigational in the absence of stronger evidence.
In the provided excerpts there are no explicit statements labeled as 'not medically necessary' beyond the investigational coverage stance; coding and reporting instructions appear but do not state additional formal 'not medically necessary' language in these chunks.
Coding and Procedure Reporting
| No codes listed |
| 64999 | Unlisted procedure, nervous system |
| None |
Provider Requirements, Billing and Documentation
Prior Authorization and Coding
Prior authorization is required for implantation procedures. Report services using appropriate CPT/HCPCS; when no specific CPT exists for the procedure, report using unlisted procedure code 64999 (Unlisted procedure, nervous system). Failure to obtain prior authorization or to use appropriate coding may result in claim denial.
- Prior authorization required for implantation and associated procedures
- If no specific CPT exists, report with 64999 (Unlisted procedure, nervous system)
- Use appropriate HCPCS, Revenue and ICD-10 diagnosis codes as applicable
Investigational — Denial Risk
Peripheral subcutaneous field stimulation is considered investigational for all indications. Procedures or services for investigational indications are subject to denial. Providers should verify coverage prior to proceeding and ensure documentation supports medical necessity; absence of supportive documentation may lead to claim denial.
- Investigational — services are not covered and may be denied
- Confirm coverage and submit prior authorization when applicable
Conservative Therapy Expectation
Conservative therapy is expected prior to consideration of peripheral subcutaneous field stimulation. Typical conservative treatments include pharmacologic management (opioids and nonopioid analgesics, antidepressants, anticonvulsants, muscle relaxants) and nonpharmacologic therapies (physical therapy, exercise, cognitive-behavioral therapy, acupuncture, chiropractic, therapeutic massage). Trial stimulation with percutaneous leads is generally required before permanent implantation and trials typically require at least a 7-day period with ≥50% pain reduction to proceed to permanent implantation.
- Document prior conservative treatments and failure to respond before authorization
- Trial stimulation usually required: at least 7 days and ≥50% pain reduction before permanent implantation
Conservative Therapy Expectations and Selection Criteria
Key Terms and Definitions
Procedure Frequency and Implantation Notes
Imaging and Pre-procedure Evaluations
PSFS — none specified
No patient selection/follow-up scales (PSFS) are specified in these policy excerpts.
Imaging requirements — none specified
No specific imaging requirements are stated in the cited policy text.
No imaging requirements specified
The policy text and referenced chunks do not list any imaging requirements for PSFS in this portion of the document.
Background and Rationale
Peripheral subcutaneous field stimulation (PSFS) is a neuromodulation modification of peripheral nerve stimulation in which leads are placed subcutaneously within the area of maximal pain to stimulate cutaneous afferents or dermatomal distributions with the goal of modulating pain signals.
Not Covered / Exclusions
Peripheral subcutaneous field stimulation is designated in this policy as investigational for all indications and therefore is listed as not covered. Providers should use appropriate reporting codes (for example, unlisted CPT 64999 when no specific CPT exists) when submitting claims, but requests remain subject to denial because of the investigational stance.
As reflected in the policy, peripheral subcutaneous field stimulation is considered investigational for all indications and is therefore treated as not covered; coding guidance in the document references the unlisted procedure code 64999 for nervous system procedures when a specific CPT is not available.
The provided excerpts do not enumerate specific procedures or indications beyond the general investigational/not covered designation; no additional explicit 'not covered' procedures or indications are listed in these chunks.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.